Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Innoviva, Inc. (INVA : NSDQ)
 
 • Company Description   
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.

Number of Employees: 159

 
 • Price / Volume Information   
Yesterday's Closing Price: $22.96 Daily Weekly Monthly
20 Day Moving Average: 859,989 shares
Shares Outstanding: 74.77 (millions)
Market Capitalization: $1,716.70 (millions)
Beta: 0.42
52 Week High: $25.15
52 Week Low: $16.52
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 14.80% 15.80%
12 Week 10.70% 10.57%
Year To Date 14.86% 14.30%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1350 OLD BAYSHORE HIGHWAY SUITE 400
-
BURLINGAME,CA 94010
USA		 ph: 650-238-9600
fax: 650-827-8690		 innoviva@argotpartners.com http://www.inva.com
 
 • General Corporate Information   
Officers
Pavel Raifeld - Chief Executive Officer
Mark DiPaolo - Chairman
Stephen Basso - Chief Financial Officer
Jules Haimovitz - Director
Sarah Schlesinger - Director

Peer Information
Innoviva, Inc. (AGN.)
Innoviva, Inc. (NVS)
Innoviva, Inc. (NVO)
Innoviva, Inc. (LLY)
Innoviva, Inc. (RHHBY)
Innoviva, Inc. (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 45781M101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/25
Next Expected EPS Date: 05/06/26
Share - Related Items
Shares Outstanding: 74.77
Most Recent Split Date: (:1)
Beta: 0.42
Market Capitalization: $1,716.70 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.44 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $2.08 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/06/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 11.04
Trailing 12 Months: 5.68
PEG Ratio: -
Price Ratios
Price/Book: 1.46
Price/Cash Flow: 4.57
Price / Sales: 4.17
EPS Growth
vs. Year Ago Period: 240.35%
vs. Previous Quarter: 79.63%
Sales Growth
vs. Year Ago Period: 24.84%
vs. Previous Quarter: 6.32%
ROE
12/31/25 - 37.63
09/30/25 - 28.17
06/30/25 - 18.67
ROA
12/31/25 - 23.60
09/30/25 - 16.23
06/30/25 - 9.92
Current Ratio
12/31/25 - 14.64
09/30/25 - 14.12
06/30/25 - 2.64
Quick Ratio
12/31/25 - 13.85
09/30/25 - 13.33
06/30/25 - 2.44
Operating Margin
12/31/25 - 81.07
09/30/25 - 55.53
06/30/25 - 34.31
Net Margin
12/31/25 - 65.92
09/30/25 - 32.78
06/30/25 - 10.44
Pre-Tax Margin
12/31/25 - 79.46
09/30/25 - 40.29
06/30/25 - 17.71
Book Value
12/31/25 - 15.69
09/30/25 - 13.51
06/30/25 - 11.34
Inventory Turnover
12/31/25 - 2.47
09/30/25 - 1.93
06/30/25 - 1.58
Debt-to-Equity
12/31/25 - 0.22
09/30/25 - 0.25
06/30/25 - 0.36
Debt-to-Capital
12/31/25 - 18.02
09/30/25 - 20.31
06/30/25 - 26.45
 

Powered by Zacks Investment Research ©